Consumerlab.com & echinacea
Five of 11 echinacea products fall short in examination by online testing firm, with lower-than-claimed amounts of compounds such as echinacosides and phenols the most common failing. Consumerlab gave a thumbs up to echinacea supplements marketed under the Nature's Resource, Nutrilite, Puritan's Pride, Sundown and Vitamin World brands. President Tod Cooperman, MD, says negative results may arise because "the wrong plant species or plant part may be used; levels of important plant chemicals may be low if the herb is not properly grown, harvested, processed, shipped and stored; and lead levels may be high due to contaminated soil"...
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
The European Medicines Agency’s ongoing pilot to streamline drug reviews by allowing companies to voluntarily pre-fill factual data in assessment report templates appears to add significant workload for industry, without delivering clear value to regulators.
Talks between the UK government and the pharmaceutical industry that were intended to resolve issues around high clawback rates under the voluntary pricing scheme for branded medicines have failed, meaning that the mechanism used to calculate rebates will remain in place.
After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.